{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T06:47:33Z","timestamp":1774507653501,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T00:00:00Z","timestamp":1574812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T00:00:00Z","timestamp":1574812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Takeda Farmac\u00e9utica Espa\u00f1a S.A."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We aimed to evaluate the prevalence, characteristics and impact of breakthrough pain (BTP) in patients with cancer attending the main specialties involved in the diagnosis and management of BTP in Spain using a multicenter, observational, cross-sectional, multidisciplinary study. Investigators had to record all patients seen at the clinic during 1 month, determine whether the patients had cancer pain, and apply the Davies algorithm to ascertain whether the patients were suffering from BTP. Of the 3,765 patients with cancer, 1,117 (30%) had cancer-related pain, and of these patients, 539 had BTP (48%, 95%CI:45\u201351). The highest prevalence was found in patients from palliative care (61%, 95%CI:54\u201368), and the lowest was found in those from hematology (25%, 95%CI:20\u201331). Prevalence varied also according to sex and type of tumor. According to the Alberta Breakthrough Pain Assessment Tool duration, timing, frequency, location, severity, quality, causes, and predictability of the BTP varied greatly among these patients. BTP was moderate (Brief Pain Inventory [BPI]-severity median score\u2009=\u20095.3), and pain interference was moderate (BPI-interference median score\u2009=\u20096.1) with a greater interference with normal work, general activity, and enjoyment of life. Patients with BTP showed a mean\u2009\u00b1\u2009standard deviation score of 28.5\u2009\u00b1\u20098.0 and 36.9\u2009\u00b1\u20099.5 in the physical and mental component, respectively, of the SF-12 questionnaire. In conclusion, prevalence of BTP among patients exhibiting cancer-related pain is high. Clinical presentation is heterogeneous, and therefore, BTP cannot be considered as a single entity. However, uniformly BTP has an important impact on a patient\u2019s functionality, which supports the need for early detection and treatment.<\/jats:p>","DOI":"10.1038\/s41598-019-54195-x","type":"journal-article","created":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T11:02:46Z","timestamp":1574852566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Prevalence and characterization of breakthrough pain in patients with cancer in Spain: the CARPE-DIO study"],"prefix":"10.1038","volume":"9","author":[{"given":"Concepci\u00f3n","family":"P\u00e9rez-Hern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Blasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"G\u00e1ndara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Ma\u00f1as","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel Jes\u00fas","family":"Rodr\u00edguez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alonso","family":"Fernandez-Nistal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Montoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,27]]},"reference":[{"key":"54195_CR1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ejpain.2008.06.014","volume":"13","author":"AN Davies","year":"2009","unstructured":"Davies, A. N., Dickman, A., Reid, C., Stevens, A. M. & Zeppetella, G. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 13, 331\u2013338, https:\/\/doi.org\/10.1016\/j.ejpain.2008.06.014 (2009).","journal-title":"Eur J Pain"},{"key":"54195_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4321\/S1134-80462013000200005","volume":"20","author":"Y Escobar \u00c1lvarez","year":"2013","unstructured":"Escobar \u00c1lvarez, Y. et al. Diagn\u00f3stico y tratamiento del dolor irruptivo oncol\u00f3gico: recomendaciones de consenso. Revista de la Sociedad Espa\u00f1ola del Dolor 20, 61\u201368 (2013).","journal-title":"Revista de la Sociedad Espa\u00f1ola del Dolor"},{"key":"54195_CR3","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jpainsymman.2015.12.329","volume":"51","author":"ET Lohre","year":"2016","unstructured":"Lohre, E. T. et al. From \u201cBreakthrough\u201d to \u201cEpisodic\u201d Cancer Pain? A European Association for Palliative Care Research Network Expert Delphi Survey Toward a Common Terminology and Classification of Transient Cancer Pain Exacerbations. J Pain Symptom Manage 51, 1013\u20131019, https:\/\/doi.org\/10.1016\/j.jpainsymman.2015.12.329 (2016).","journal-title":"J Pain Symptom Manage"},{"key":"54195_CR4","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s12094-015-1468-7","volume":"18","author":"J Porta-Sales","year":"2016","unstructured":"Porta-Sales, J., Perez, C., Escobar, Y. & Martinez, V. Diagnosis and management of breakthrough cancer pain: Have all the questions been resolved? A Delphi-based consensus assessment (DOIRON). Clin Transl Oncol 18, 945\u2013954, https:\/\/doi.org\/10.1007\/s12094-015-1468-7 (2016).","journal-title":"Clin Transl Oncol"},{"key":"54195_CR5","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/aco.0000000000000224","volume":"28","author":"S Mercadante","year":"2015","unstructured":"Mercadante, S. Breakthrough pain in cancer patients: prevalence, mechanisms and treatment options. Curr Opin Anaesthesiol 28, 559\u2013564, https:\/\/doi.org\/10.1097\/aco.0000000000000224 (2015).","journal-title":"Curr Opin Anaesthesiol"},{"key":"54195_CR6","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.pain.2010.02.035","volume":"149","author":"DF Haugen","year":"2010","unstructured":"Haugen, D. F., Hjermstad, M. J., Hagen, N., Caraceni, A. & Kaasa, S. Assessment and classification of cancer breakthrough pain: a systematic literature review. Pain 149, 476\u2013482, https:\/\/doi.org\/10.1016\/j.pain.2010.02.035 (2010).","journal-title":"Pain"},{"key":"54195_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jpainsymman.2013.02.015","volume":"47","author":"S Deandrea","year":"2014","unstructured":"Deandrea, S. et al. Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature. J Pain Symptom Manage 47, 57\u201376, https:\/\/doi.org\/10.1016\/j.jpainsymman.2013.02.015 (2014).","journal-title":"J Pain Symptom Manage"},{"key":"54195_CR8","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jpainsymman.2012.12.009","volume":"46","author":"A Davies","year":"2013","unstructured":"Davies, A. et al. Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manage 46, 619\u2013628, https:\/\/doi.org\/10.1016\/j.jpainsymman.2012.12.009 (2013).","journal-title":"J Pain Symptom Manage"},{"key":"54195_CR9","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1007\/s00520-013-1817-4","volume":"21","author":"G Bedard","year":"2013","unstructured":"Bedard, G. et al. A survey of Canadian cancer patients\u2019 perspectives on the characteristics and treatment of breakthrough pain. Support Care Cancer 21, 2557\u20132563, https:\/\/doi.org\/10.1007\/s00520-013-1817-4 (2013).","journal-title":"Support Care Cancer"},{"key":"54195_CR10","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s00520-014-2178-3","volume":"22","author":"SX Raj","year":"2014","unstructured":"Raj, S. X. et al. A cross-sectional study on prevalence of pain and breakthrough pain among an unselected group of outpatients in a tertiary cancer clinic. Support Care Cancer 22, 1965\u20131971, https:\/\/doi.org\/10.1007\/s00520-014-2178-3 (2014).","journal-title":"Support Care Cancer"},{"key":"54195_CR11","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00520-014-2426-6","volume":"23","author":"G Bedard","year":"2015","unstructured":"Bedard, G. et al. Breakthrough cancer pain: a comparison of surveys with European and Canadian patients. Support Care Cancer 23, 791\u2013796, https:\/\/doi.org\/10.1007\/s00520-014-2426-6 (2015).","journal-title":"Support Care Cancer"},{"key":"54195_CR12","doi-asserted-by":"publisher","unstructured":"Mercadante, S. et al. Factors Influencing the Clinical Presentation of Breakthrough Pain in Cancer Patients. Cancers (Basel) 10, https:\/\/doi.org\/10.3390\/cancers10060175 (2018).","DOI":"10.3390\/cancers10060175"},{"key":"54195_CR13","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1136\/bmjspcare-2015-000887","volume":"6","author":"MJ Hjermstad","year":"2016","unstructured":"Hjermstad, M. J. et al. Characteristics of breakthrough cancer pain and its influence on quality of life in an international cohort of patients with cancer. BMJ Support. Palliat Care 6, 344\u2013352, https:\/\/doi.org\/10.1136\/bmjspcare-2015-000887 (2016).","journal-title":"Palliat Care"},{"key":"54195_CR14","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1089\/jpm.2017.0675","volume":"21","author":"K Tagami","year":"2018","unstructured":"Tagami, K. et al. Breakthrough Cancer Pain Influences General Activities and Pain Management: A Comparison of Patients with and without Breakthrough Cancer Pain. J Palliat Med 21, 1636\u20131640, https:\/\/doi.org\/10.1089\/jpm.2017.0675 (2018).","journal-title":"J Palliat Med"},{"key":"54195_CR15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3109\/15360288.2013.787137","volume":"27","author":"KL Kuo","year":"2013","unstructured":"Kuo, K. L., Saokaew, S. & Stenehjem, D. D. The pharmacoeconomics of breakthrough cancer pain. J Pain Palliat Care Pharmacother 27, 167\u2013175, https:\/\/doi.org\/10.3109\/15360288.2013.787137 (2013).","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"54195_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12904-018-0336-y","volume":"17","author":"J Canal-Sotelo","year":"2018","unstructured":"Canal-Sotelo, J. et al. Prevalence and characteristics of breakthrough cancer pain in an outpatient clinic in a Catalan teaching hospital: incorporation of the Edmonton Classification System for Cancer pain into the diagnostic algorithm. BMC Palliat Care 17, 81, https:\/\/doi.org\/10.1186\/s12904-018-0336-y (2018).","journal-title":"BMC Palliat Care"},{"key":"54195_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-018-1925-1","author":"C Camps Herrero","year":"2018","unstructured":"Camps Herrero, C. et al. Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP). Clin Transl Oncol. https:\/\/doi.org\/10.1007\/s12094-018-1925-1 (2018).","journal-title":"Clin Transl Oncol"},{"key":"54195_CR18","doi-asserted-by":"crossref","unstructured":"Badia, X. et al. Validation of the Spanish version of the Brief Pain Inventory in patients with oncological pain. Med Clin (Barc) 120, 52\u201359, S0025-7753(03)73601-X [pii] (2003).","DOI":"10.1016\/S0025-7753(03)73601-X"},{"key":"54195_CR19","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jpainsymman.2007.03.016","volume":"35","author":"NA Hagen","year":"2008","unstructured":"Hagen, N. A. et al. The Alberta Breakthrough Pain Assessment Tool for cancer patients: a validation study using a delphi process and patient think-aloud interviews. J Pain Symptom Manage 35, 136\u2013152, https:\/\/doi.org\/10.1016\/j.jpainsymman.2007.03.016 (2008).","journal-title":"J Pain Symptom Manage"},{"key":"54195_CR20","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/ejp.612","volume":"19","author":"R Sperlinga","year":"2015","unstructured":"Sperlinga, R. et al. Alberta Breakthrough Pain Assessment Tool: A validation multicentre study in cancer patients with breakthrough pain. Eur J Pain 19, 881\u2013888, https:\/\/doi.org\/10.1002\/ejp.612 (2015).","journal-title":"Eur J Pain"},{"key":"54195_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/JCO.1984.2.3.187","volume":"2","author":"CC Schag","year":"1984","unstructured":"Schag, C. C., Heinrich, R. L. & Ganz, P. A. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 2, 187\u2013193, https:\/\/doi.org\/10.1200\/JCO.1984.2.3.187 (1984).","journal-title":"J Clin Oncol"},{"key":"54195_CR22","doi-asserted-by":"crossref","unstructured":"Vilagut, G. et al. Interpretation of SF-36 and SF-12 questionnaires in Spain: physical and mental components. Med Clin (Barc) 130, 726\u2013735, S0025-7753(08)71563-X [pii] (2008).","DOI":"10.1157\/13121076"},{"key":"54195_CR23","unstructured":"Vilagut, G. et al. The Spanish version of the Short Form 36 Health Survey: a decade of experience and new developments. Gac Sanit 19, 135\u2013150, 13074370 [pii] (2005)."},{"key":"54195_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/AJP.0b013e3181edc250","volume":"27","author":"MT Greco","year":"2011","unstructured":"Greco, M. T. et al. Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients: results from the Cancer Pain Outcome Research Study Group. Clin J Pain 27, 9\u201318, https:\/\/doi.org\/10.1097\/AJP.0b013e3181edc250 (2011).","journal-title":"Clin J Pain"},{"key":"54195_CR25","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jpainsymman.2011.05.018","volume":"43","author":"A Caraceni","year":"2012","unstructured":"Caraceni, A. et al. Episodic (breakthrough) pain prevalence in a population of cancer pain patients. Comparison of clinical diagnoses with the QUDEI\u2013Italian questionnaire for intense episodic pain. J Pain Symptom Manage 43, 833\u2013841, https:\/\/doi.org\/10.1016\/j.jpainsymman.2011.05.018 (2012).","journal-title":"J Pain Symptom Manage"},{"key":"54195_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.5055\/jom.2010.0009","volume":"6","author":"RK Portenoy","year":"2010","unstructured":"Portenoy, R. K., Bruns, D., Shoemaker, B. & Shoemaker, S. A. Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristics. J Opioid Manag 6, 97\u2013108 (2010).","journal-title":"J Opioid Manag"},{"key":"54195_CR27","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.jpainsymman.2015.12.340","volume":"51","author":"MH van den Beuken-van Everdingen","year":"2016","unstructured":"van den Beuken-van Everdingen, M. H., Hochstenbach, L. M., Joosten, E. A., Tjan-Heijnen, V. C. & Janssen, D. J. Update on Prevalence of Pain in Patients With Cancer: Systematic Review and Meta-Analysis. J Pain Symptom Manage. 51, 1070\u20131090, https:\/\/doi.org\/10.1016\/j.jpainsymman.2015.12.340 (2016).","journal-title":"J Pain Symptom Manage."},{"key":"54195_CR28","doi-asserted-by":"publisher","unstructured":"Breivik, H. et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol 20, 1420\u20131433, https:\/\/doi.org\/10.1093\/annonc\/mdp001mdp001.","DOI":"10.1093\/annonc\/mdp001mdp001"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54195-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54195-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54195-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T16:28:40Z","timestamp":1671294520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54195-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,27]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["54195"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-54195-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,27]]},"assertion":[{"value":"16 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Concepci\u00f3n P\u00e9rez Hern\u00e1ndez, Ana Blasco Cordellat, \u00c1lvaro G\u00e1ndara del Castillo, Ana Ma\u00f1as Rueda, and Manuel Jes\u00fas Rodr\u00edguez L\u00f3pez have received consultant fees for coordinating this study. Vicente Mart\u00ednez, Alonso Fernandez-Nistal, and Carmen Montoto are full-time employees of Takeda Farmac\u00e9utica Espa\u00f1a S.A.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17701"}}